This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Lipoprotein a (lpa)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Lipoprotein A (Lp (a)) is an LDL-like particle that contains apolipoprotein (a) in addition to apo B

  • apo(a) component is encoded by the LPA gene, and levels of Lp(a) are almost entirely explained by genetics

Lp (a) is produced in the liver; its significance lies in the fact that numerous studies have found that concentrations of plasma Lp (a) above 0.3 g/l (note reference ranges may vary between laboratories) are associated with an increased risk of coronary heart disease.

Up to 20% of the population have an increased level of Lp (a)

  • 1 in 5 individuals affected in the United States [ie, based on Lp(a) > 0.5g/l or >120 nmol/L] (1)

Concentrations vary from almost undetectable to greater than 1 g/l; differing little with sex, body mass index and age in adults.

Epidemiological evidence has linked Lp(a) to several cardiovascular diseases (1)

  • including myocardial infarction (MI), stroke, and aortic valve stenosis
  • findings from a Mendelian randomization study suggest that elevated Lp(a) may directly contribute to CHD development
  • Lp(a) levels vary significantly across different ethnicities, with Africans having the highest Lp(a) levels (median 0.27 g/l ), whereas Chinese were observed to have the lowest (0.078 g/l) (3)
  • among patients with ACS, raised Lp(a) levels are associated with an increased atherosclerotic burden and it identifies a subset of patients with features of high-risk coronary atherosclerosis (2)
  • association between Lp(a) > 0.5g/l and MI, conferring an increased odds of MI of 48% (95% CI, 32%-67%) (3)
    • only ethnic groups that were heterogeneous were Africans and Arabs, in whom the association appeared null; however, these were the smallest subgroups and were affected by poor precision (3)
    • other evidence has revealed that Lp(a) > 0.5 g/l is a risk factor for cardiovascular disease in blacks (4)
  • evidence from FOURIER study revealed that raised Lp (a) was an independent marker of cardiovascular risk despite use of moderate or high-intensity statins (5)
    • in the well-treated FOURIER cohort, in which >99% of participants received moderate- or high-intensity statins and in which LDL cholesterol was <100 mg/dL (apoB <90 mg/dL), higher Lp(a) was associated with major adverse cardiovascular events (defined as a composite of coronary heart death, MI, or urgent coronary revascularization)
      • both the third and fourth upper quartiles of the Lp(a) distribution had an increased risk of major adverse cardiovascular events of 17% and 22%, respectively, compared with the lowest quartile
  • clinical benefit of lowering Lp(a) is likely to be proportional to the absolute reduction in Lp(a) concentration. Large absolute reductions in Lp(a) of approximately 100 mg/dL may be required to produce a clinically meaningful reduction in the risk of CHD similar in magnitude to what can be achieved by lowering LDL-C level by 38.67 mg/dL (ie, 1 mmol/L) (6)
  • PCSK9 inhibitors reduce Lp(a) concentrations (by approximately 20%-25%) in the circulation (7,8)
  • evidence of Lp(a) levels and stroke risk (9)
    • a study evaluated the association of Lp(a) with large artery atherosclerosis (LAA) stroke and risk of recurrent cerebrovascular events in acute ischaemic stroke patients
    • showed elevated Lp(a) was independently associated with LAA stroke aetiology and risk of recurrent cerebrovascular events among primarily Caucasian individuals aged <60 years or with evident arteriosclerotic disease
  • in comparison to hs-CRP (high sensitivity CRP) as an indicator of cardiovascular risk (10)
    • cohort study found in both a primary prevention population (UK Biobank) and secondary prevention populations (FOURIER [TIMI 59] and SAVOR-TIMI 53), higher Lp(a) was associated with increased risk of major adverse cardiovascular events, myocardial infarction, and peripheral artery disease regardless of baseline hs-CRP level

Levels may also be affected by:

  • hepatic disease and excessive alcohol decrease levels
  • diabetics with proteinuria and albuminuric renal disease have increased levels.

The pathway for clearance is uncertain.

Reference:

  1. Erquo S et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.JAMA. 2009 Jul 22;302(4):412-23
  2. Niccoli G et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016 Mar;246:214-20
  3. Pare G et al. Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.Circulation. 2019 Mar 19;139(12):1472-1482
  4. Guan M et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):996-1001
  5. O'Donoghue ML et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.Circulation. 2019 Mar 19;139(12):1483-1492
  6. Burgess S et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.JAMA Cardiol. 2018 Jul 1; 3(7): 619-627.
  7. Malo, J, Parajuli, A, Walker, SW. PCSK9: from molecular biology to clinical applications. Ann Clin Biochem 2020; 57: 7-26
  8. Kasichayanula, S, Grover, A, Emery, MG, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet 2018; 57: 769-779
  9. Arnold M, Schweizer J, Nakas CT et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study Eur Heart J. 2021 Mar 8;ehab081. doi: 10.1093/eurheartj/ehab081.
  10. Small AM, Pournamdari A, Melloni GE, et al. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiol. Published online February 14, 2024. doi:10.1001/jamacardio.2023.5605

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.